Eiko Lifesciences began life in 1977 as a Delhi-based investment company, but in 2020 it tore up that script entirely - changing its name, its purpose, and its main object to become a manufacturer of specialty and fine chemicals. It set up shop at a leased plant in Maharashtra and started commercial production that same year, building a business around in-house product development and a claim to being a pioneer in most of the molecules it makes. The recurring approach is visible across every subsequent move: identify a niche where specialized chemistry knowledge limits the competition, develop the product in-house, then either make it yourself or partner with someone who can - and use each new capability to open the next door, whether that means forward-integrating into finished-dose pharmaceuticals or backward-integrating into oleochemicals.
Business segments
Three engines at different stages - a specialty-chemicals core that designs and makes high-value molecules for global customers, a pharmaceutical-formulations bet that turns those molecules into finished tablets and capsules, and a logistics platform that moves containers for chemical and industrial shippers - each built by partnering rather than going it alone.
1. Specialty and fine chemicals: the knowledge-chemicals engine
Eiko makes molecules that other companies struggle to replicate - preservatives, emollients, drug intermediates, and oxidizing agents - and sells them to pharma, agrochemical, and personal-care customers in roughly eight countries.
- Limited competition by design - the company describes its products as “knowledge chemicals” that demand specialized skills in chemistry, engineering, material handling, and effluent treatment, which means there are only a handful of producers in India for the range it manufactures.
- One fungible plant, many products - manufacturing runs out of a single 41,920-square-meter facility at Badlapur, Maharashtra, where reactors, centrifuges, and dryers are designed for total fungibility, so the same equipment can switch between products as market demand shifts.
- In-house R&D as the growth engine - the R&D centre develops new molecules to customer specifications for pharmaceutical industries, Argo Chemicals, fragrance and flavors, while continuously upgrading processes to cut costs through better catalysts and lower energy use.
- Made here, made elsewhere - Eiko supplements its own plant with job-work partners who manufacture to its specifications and quality standards, and it has strategic sourcing partnerships for products it does not currently make itself.
- Preferred business partner to strategic partners - the company acts as the preferred business partner for sourcing and supplying key raw materials to its associate Reflux Pharmaceuticals and its oleochemicals partner Vivacious Pharmatex, and it co-markets newly developed products with Reflux, locking in demand for its output.
2. Pharmaceutical formulations: forward integration into finished doses
Through its 51%-owned subsidiary SSM Formulations, Eiko is moving from selling chemical intermediates to selling the finished tablets and capsules that patients actually take - a WHO-GMP-accredited plant with narcotics licences and registrations across five African and Central Asian countries.
- Bought, not built - Eiko acquired a controlling 51% stake in SSM Formulations in December 2025, gaining a ready-made facility on the Nagpur-Hyderabad highway with 80,000 square feet of built-up area and expansion-ready space.
- Room to run the machines harder - the plant is currently running at about 58% capacity for tablets and 33% for capsules, with a plan to push both above 90%, which would unlock an annual capacity of 300 crore tablets and 90 crore capsules.
- Licences and registrations already in hand - SSM holds a Narcotics License with Tramadol registrations in Ghana and Nigeria, 199 product manufacturing permissions, 157 testing permissions, and 74 COPPs with WHO-GMP certification, covering anti-diabetic, cardiac, antibiotic, pain-management, dermatology, and anti-protozoal therapies.
- Pivoting to higher-value customers - the subsidiary is shifting from low-margin job work toward government tenders (TNMSC, UPMSCL) and contract manufacturing for multinational corporations, with EU-GMP accreditation in process to open regulated Western markets.
3. Logistics: a container platform built on a long-term contract
EikoVivify Logistics, a 51%-owned joint venture, leases and manages shipping containers - dry boxes, open-tops, flat racks, and reefers - and has already locked in a five-year service agreement that is expected to generate roughly ₹65 crore in revenue.
- A joint venture with committed capital - incorporated in November 2024 with Vivify Wealth Management holding the remaining 49%, the venture’s partners have committed to investing ₹100 crore over three years to build an asset-backed container fleet.
- The anchor customer came first - in December 2024, EVL signed a five-year Container Service Management Agreement with S J Logistics, a listed logistics company with over 20 years of international experience, covering approximately 2,500 TEUs of container management.
- Fleet deployed and earning - as of July 2025, over 800 TEU containers were already in the field under long-term arrangements, serving customers across chemicals, pharmaceuticals, consumer goods, and industrial products.
Group structure and partners
Eiko operates through a parent chemicals company, three subsidiaries at different stages of maturity, and two strategic pharmaceutical partners - a structure assembled almost entirely since 2023.
- Eiko Lifesciences Ltd is the listed parent (BSE, since December 2016), headquartered in Thane, Maharashtra, and run by a board that blends chemical-industry veterans with logistics and digital-marketing expertise.
- Eiko Scientific Solutions LLP is an R&D subsidiary incorporated in May 2024, with Eiko Lifesciences Limited holding 99.99%, and board approval to invest up to ₹5 crore over three years; it was yet to commence operations as of its incorporation date.
- EikoVivify Logistics Private Limited is the 51% logistics subsidiary described in the segment above, with Vivify Wealth Management LLP holding the remaining 49%.
- SSM Formulations Private Limited is the 51% pharmaceutical-formulations subsidiary described in the segment above, acquired in December 2025.
- Reflux Pharmaceuticals Private Limited is a 25.01%-owned associate (acquired April 2024 for ₹7 crore) that makes APIs and intermediates at a partnership firm's facility, with a larger facility under development in Mahad designed to comply with USFDA, EU, WHO-Geneva, and PMDA-Japan standards across three phases and a projected reactor capacity of roughly 1,00,000 litres.
- Vivacious Pharmatex Private Limited is the oleochemicals partner; Eiko initially took a 5% stake in March 2023, then restructured the relationship in January 2024 into a minimum-three-year business agreement under which Eiko committed ₹8 crore and became the preferred sourcing and supply partner, with VPPL providing product-development and manufacturing support.